drugset / Trial / NCT03710434

AZD4635 Relative Bioavailability Study

NCT03710434

Phase 1 Completed 21 enrolled AstraZeneca Quotient Sciences · collab
RandomizedCrossoverOpen-labelBasic science

Summary

To investigate the pharmacokinetics and relative bioavailability of AZD4635 solid oral formulation and compare with the nano-suspension reference formulation with the option to assess food effect, pH effect and absolute bioavailability

Timeline

Start
2018-11-01
Primary completion
2019-04-02
Completion
2019-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 30 mg
Subject imaradenant Small molecule 50 mg Oral

Indications

No indication recorded.